Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503051 | 1.00 | TRPA1 (0.39) | TRPA1AOC3IDO1TDO2TACR1 | |
| SCHEMBL503052 | 1.00 | TRPA1 (0.39) | TRPA1AOC3IDO1TDO2TACR1 | |
| SCHEMBL1961623 | 0.83 | TACR1 (0.47) | TRPA1AOC3TACR1 | |
| SCHEMBL1961621 | 0.83 | TACR1 (0.47) | TRPA1AOC3TACR1 | |
| SCHEMBL1961619 | 0.83 | TACR1 (0.47) | TRPA1AOC3TACR1 | |
| SCHEMBL502851 | 0.81 | KDM4E (0.40) | TRPA1AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL503040 | 0.81 | KDM4E (0.40) | TRPA1AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL502850 | 0.81 | KDM4E (0.40) | TRPA1AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL574797 | 0.81 | KDM4E (0.40) | TRPA1AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1833604 | 0.78 | TRPA1 (0.51) | TRPA1IDO1MAOAMAOBSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132136-B2 | Pharmaceutical combination | HOFFMANN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130345201-A1 | PHARMACEUTICAL COMBINATION | HOFFMANN-LA ROCHE INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-20120028964-A1 | PHARMACEUTICAL COMBINATION | SEMINIS VEGETABLE SEEDS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028964-A1 | PHARMACEUTICAL COMBINATION | TAAR1, TAAR5, MC2R | TRPA1 776/4885AOC3 377/4885IDO1 660/4885 |
| US-20130345201-A1 | PHARMACEUTICAL COMBINATION | TAAR1, TAAR5, MC2R | TRPA1 776/4885AOC3 377/4885IDO1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.